David Brian Perez
Known title: DirectorCIK: 0001765355
David Brian Perez's purchase track record
David Brian Perez has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/5/2025 | NEO | $76K | -27.7% | +24.7% | +21.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NEO | ▲ Buy | Option Exercise | 23,077 | $0 | 6/1/2026 | View on chart |
| NEO | ▲ Buy | Option Exercise | 12,254 | $0 | 6/1/2025 | View on chart |
| NEO | ▲ Buy | Open Market | 10,000 | $76K | 5/5/2025 | View on chart |
| NEO | ▲ Buy | Option Exercise | 11,336 | $0 | 8/10/2024 | View on chart |
| NEO | ▲ Buy | Grant | 10,300 | $0 | 11/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News
NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.